Payment overview · 2025
General Payments
$1,643.03
75 reported records · 22 companies
Healthcare provider profile · identity verified
Richard Samuel Gold, MD
Allopathic & Osteopathic Physicians|Internal Medicine · SMITHTOWN, NY · NPI 1184796310
Verified facts
What the public records show
CMS Open Payments records show Richard Samuel Gold, MD received $1,643.03 in general payments during 2025 across 75 reported records.
Novo Nordisk Inc accounted for 13.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 36 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Gemtesa, Jardiance, Mounjaro, Ozempic, Paxlovid, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 96 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Entresto by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 355 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 74 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $221.98 | 13.5% | 11 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $189.38 | 11.5% | 11 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $167.32 | 10.2% | 9 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $142.44 | 8.7% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $131.09 | 8.0% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $108.88 | 6.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $108.67 | 6.6% | 4 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $102.66 | 6.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $62.40 | 3.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $55.53 | 3.4% | 2 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $53.57 | 3.3% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $50.97 | 3.1% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $39.38 | 2.4% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.19 | 2.2% | 2 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.97 | 1.8% | 1 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $27.02 | 1.6% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.43 | 1.4% | 1 | 2025 |
| Seqirus USA Inc | Unresolved — no canonical attribution shown | $21.75 | 1.3% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $19.66 | 1.2% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $18.58 | 1.1% | 1 | 2025 |
| Phadia US Inc. | Unresolved — no canonical attribution shown | $17.68 | 1.1% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $14.48 | 0.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,643.03 | 75 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $167.32 | 9 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $157.81 | 8 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $142.44 | 5 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $136.94 | 7 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $108.88 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $108.67 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $106.03 | 6 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $106.03 | 6 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $87.70 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $86.29 | 3 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $64.17 | 3 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $62.40 | 3 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $62.40 | 3 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $55.53 | 2 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $53.57 | 2 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $53.03 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $53.03 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $53.03 | 3 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $50.97 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $44.80 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $44.80 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $39.38 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $36.19 | 2 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $30.32 | 2 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| HETLIOZ Normalized: hetlioz |
Drug | Vanda Pharmaceuticals Inc. | $29.97 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $27.02 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $23.43 | 1 | 2025 |
Source payment records
|
|||||
| Fluad Normalized: fluad |
Biological | Seqirus USA Inc | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| Flucelvax Normalized: flucelvax |
Biological | Seqirus USA Inc | $21.75 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $19.66 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $18.58 | 1 | 2025 |
Source payment records
|
|||||
| ImmunoCAP Normalized: immunocap |
Device | Phadia US Inc. | $17.68 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.96 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $14.48 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 355 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 96 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 74 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 73 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 | exact normalized | Medicare Part D |
| PAXLOVID paxlovid |
2025 | Paxlovid | 2024 | 13 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 23 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
96 | 24 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
12 | 12 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
35 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
73 | 11 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
355 | 57 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
74 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 705 | 205 |
| Amlodipine Besylate | Amlodipine Besylate | 453 | 129 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 407 | 140 |
| Eliquis | Apixaban | 355 | 57 |
| Levothyroxine Sodium | Levothyroxine Sodium | 337 | 84 |
| Losartan Potassium | Losartan Potassium | 324 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 314 | 91 |
| Tramadol Hcl | Tramadol Hcl | 284 | 51 |
| Gabapentin | Gabapentin | 264 | 56 |
| Alprazolam | Alprazolam | 253 | 70 |
| Furosemide | Furosemide | 184 | 59 |
| Oxycodone Hcl | Oxycodone Hcl | 183 | 28 |
| Metformin Hcl | Metformin Hcl | 171 | 45 |
| Lorazepam | Lorazepam | 166 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 162 | 33 |
| Tamsulosin Hcl | Tamsulosin Hcl | 160 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 159 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 155 | 30 |
| Lisinopril | Lisinopril | 140 | 32 |
| Zolpidem Tartrate | Zolpidem Tartrate | 135 | 24 |
| Carvedilol | Carvedilol | 133 | 47 |
| Simvastatin | Simvastatin | 127 | 39 |
| Prednisone | Prednisone | 125 | 53 |
| Ezetimibe | Ezetimibe | 124 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 46 |
| Donepezil Hcl | Donepezil Hcl | 117 | 23 |
| Omeprazole | Omeprazole | 110 | 48 |
| Pantoprazole Sodium | Pantoprazole Sodium | 103 | 44 |
| Sertraline Hcl | Sertraline Hcl | 101 | 28 |
| Meloxicam | Meloxicam | 99 | 45 |
| Xarelto | Rivaroxaban | 98 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 97 | 26 |
| Farxiga | Dapagliflozin Propanediol | 96 | 24 |
| Pregabalin | Pregabalin | 95 | suppressed |
| Mirtazapine | Mirtazapine | 93 | 25 |
| Trazodone Hcl | Trazodone Hcl | 92 | 19 |
| Metformin Hcl Er | Metformin Hcl | 91 | 32 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 88 | 33 |
| Retacrit | Epoetin Alfa-Epbx | 83 | suppressed |
| Gemtesa | Vibegron | 74 | suppressed |
| Mounjaro | Tirzepatide | 73 | 11 |
| Spironolactone | Spironolactone | 72 | 21 |
| Potassium Chloride | Potassium Chloride | 71 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 69 | 24 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 12 |
| Alogliptin | Alogliptin Benzoate | 68 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 67 | 41 |
| Glimepiride | Glimepiride | 66 | 19 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 66 | 40 |
| Januvia | Sitagliptin Phosphate | 66 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 66 | 65 |
| Quetiapine Fumarate | Quetiapine Fumarate | 65 | 15 |
| Memantine Hcl | Memantine Hcl | 64 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 60 | 24 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 59 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 58 | suppressed |
| Ramipril | Ramipril | 58 | 18 |
| Azithromycin | Azithromycin | 56 | 49 |
| Atenolol | Atenolol | 54 | 11 |
| Levetiracetam | Levetiracetam | 54 | suppressed |
| Finasteride | Finasteride | 53 | 19 |
| Allopurinol | Allopurinol | 52 | 23 |
| Famotidine | Famotidine | 52 | 27 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 52 | suppressed |
| Cephalexin | Cephalexin | 49 | 19 |
| Methocarbamol | Methocarbamol | 49 | 23 |
| Fluticasone Propionate | Fluticasone Propionate | 47 | 27 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 45 | 16 |
| Phenobarbital | Phenobarbital | 45 | suppressed |
| Torsemide | Torsemide | 45 | 15 |
| Clonazepam | Clonazepam | 44 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 43 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 42 | 15 |
| Baclofen | Baclofen | 42 | suppressed |
| Valsartan | Valsartan | 42 | 12 |
| Diltiazem 24hr Er | Diltiazem Hcl | 41 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 38 | 16 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Lacosamide | Lacosamide | 36 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 35 | suppressed |
| Levofloxacin | Levofloxacin | 35 | 20 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 18 |
| Vascepa | Icosapent Ethyl | 34 | suppressed |
| Entresto | Sacubitril/Valsartan | 33 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 33 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 32 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 32 | 22 |
| Celecoxib | Celecoxib | 31 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 31 | suppressed |
| Atovaquone | Atovaquone | 30 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | suppressed |
| Nuplazid | Pimavanserin Tartrate | 30 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 29 | suppressed |
| Ozempic | Semaglutide | 28 | 12 |
| Admelog Solostar | Insulin Lispro | 27 | suppressed |
| Nystatin | Nystatin | 27 | 11 |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Glipizide | Glipizide | 26 | suppressed |
| Insulin Glargine-Yfgn | Insulin Glargine-Yfgn | 26 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 25 | 12 |
| Ketoconazole | Ketoconazole | 25 | suppressed |
| Myrbetriq | Mirabegron | 24 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 24 | 20 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 23 | 13 |
| Niacin Er | Niacin | 23 | suppressed |
| Perindopril Erbumine | Perindopril Erbumine | 23 | suppressed |
| Rybelsus | Semaglutide | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 17 |
| Jardiance | Empagliflozin | 22 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 22 | suppressed |
| Nifedipine Er | Nifedipine | 22 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 22 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 21 | suppressed |
| Mupirocin | Mupirocin | 21 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 20 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 20 | 17 |
| Citalopram Hbr | Citalopram Hydrobromide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 20 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 19 | suppressed |
| Latanoprost | Latanoprost | 19 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 19 | suppressed |
| Phenytoin | Phenytoin | 19 | suppressed |
| Rytary | Carbidopa/Levodopa | 19 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 19 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 19 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Namzaric | Memantine Hcl/Donepezil Hcl | 18 | suppressed |
| Olanzapine | Olanzapine | 18 | suppressed |
| Pradaxa | Dabigatran Etexilate Mesylate | 18 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 17 | suppressed |
| Nyamyc | Nystatin | 17 | suppressed |
| Timolol Maleate | Timolol Maleate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 16 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 16 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 16 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Risperidone | Risperidone | 16 | suppressed |
| Sodium Chloride | Sodium Chloride 0.45 % | 16 | 13 |
| Trandolapril | Trandolapril | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 15 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Digoxin | Digoxin | 14 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 14 | suppressed |
| Methylprednisolone | Methylprednisolone | 14 | 14 |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 13 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 13 | suppressed |
| Lidocaine | Lidocaine | 13 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 13 | 12 |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Ropinirole Hcl | Ropinirole Hcl | 13 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 13 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 12 | 12 |
| Breo Ellipta | Fluticasone/Vilanterol | 12 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 12 | suppressed |
| Eplerenone | Eplerenone | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 12 | suppressed |
| Repaglinide | Repaglinide | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 12 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Chlorthalidone | Chlorthalidone | 11 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 11 | suppressed |
| Posaconazole | Posaconazole | 11 | suppressed |
| Rivastigmine | Rivastigmine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,643.03 · 75 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, ELIQUIS, FANAPT, FARXIGA, Fluad, Flucelvax, GARDASIL 9, GEMTESA, HETLIOZ, IBSRELA, ImmunoCAP, JARDIANCE, LEQVIO, MOUNJARO, NEXLETOL, NURTEC ODT, OTEZLA, Ozempic, PAXLOVID, PREVNAR 20, REPATHA, REXULTI, Rybelsus, TRELEGY ELLIPTA, UZEDY, VRAYLAR, Veozah, WATCHMAN FLX, Wegovy, XIFAXAN, ZEPBOUND, ZORYVE | 14 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error